Skip to main content

Home/ MaRS/ Group items tagged Board Members

Rss Feed Group items tagged

Assunta Krehl

Toronto's $25 million commercialization "engine" celebrates the appointment of its Boar... - 0 views

  • MaRS Innovation is honoured to announce its permanent Board of Directors, who brings together a remarkable and broad set of experiences and networks to support the development of this dynamic partnership of Toronto research institutions.  Designed to enhance the commercial output of Toronto’s world-leading research cluster, MaRS Innovation is positioned to make a significant contribution to Canada’s innovation economy and the quality of life for Canadians and others around the world.
  • upported by the Government of Canada through the Centres of Excellence in Research and Commercialization (CECR) program, and its member institutions, MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. The newly appointed Board of Directors, which includes academic and business leaders from across Canada and the United States, has the targeted expertise to guide MaRS Innovation to deliver on this critical mission.   MaRS Innovation represents a unique collaborative model, which aggregates the exceptional discovery pipeline of 14 leading Toronto academic institutions to build a diversified portfolio of assets, and harness the economic and job creation potential of the best opportunities for Toronto, Ontario and Canada.
  • “MaRS Innovation is privileged to announce a Board of Directors of this caliber and breadth of skill,” said Mary Jo Haddad, Chair of the MaRS Innovation Board and President and CEO of The Hospital for Sick Children. “The collective experience and guidance of these individuals will be critical to developing a collaborative, integrated and agile approach to this transformational organization that will move Canada into its next phase of economic development.”
  • ...2 more annotations...
  • W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto
  • MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.
  •  
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs.
  •  
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. Feb 6, 2009
Assunta Krehl

Dr. Calvin Stiller appointed Chair of Board of Directors - Ontario Institute for Cancer... - 0 views

  • The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board.
  • He succeeds Dr. John Evans, who was the first Chair and who will continue to serve as a board member.
  • Dr. Stiller co-founded the MaRS Centre in Toronto
  •  
    The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board. Mention of Dr. Stiller Co-Founding MaRS.
  •  
    The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board. Mention of Dr. Stiller Co-Founding MaRS. Jan 21, 2009
Assunta Krehl

Announcement - Canada's Outstanding CEO of the Year? Award Program 2009 - National Post - 0 views

  • The Caldwell Partners, Deloitte and National Post are pleased to announce the appointment of Gordon M. Nixon to Canada's Outstanding CEO of theYearTM Advisory Board for 2009.
  • Mr. Nixon is Chairman of the Canadian Council of Chief Executives, Chairman of MaRS Discovery District, and is on the Board of Directors of The Hospital for Sick Children, The International Monetary Conference, Catalyst Canada and is on the Advisory Board of Mercedes-Benz Canada.
  •  
    Announcement regarding the appointment of Gordon M. Nixon to Canada's Outstanding CEO of theYearTM Advisory Board for 2009. Sept 2, 2009
Assunta Krehl

MEDEC appoints Peter Robertson as Chair of the MEDEC Board of Directors - Digital Journ... - 0 views

  •  
    "Peter Robertson as Chair of the MEDEC Board of Directors. Peter Robertson is Vice President and General Manager of GE Healthcare Canada. Peter is also a member of the management board for MaRS' Excellence in Clinical Innovation and Technology Evaluation (""EXCITE"") program."
Assunta Krehl

ARISE Technologies Announces Appointment of New Chairman and Changes to Senior Manageme... - 0 views

  •  
    RISE Technologies Corporation, a leader in high-performance, high-quality, cost-effective solar technology, today announced the appointment of Mr. Peter Harder as Chairman of the Company's Board of Directors. Mention of William White being on the Board of Directors for MaRS Discovery District. Nov 11, 2009
Karen Schulman Dupuis

Media Advisory: Governor General to Invest 44 Recipients Into the Order of Canada - Mar... - 1 views

  •  
    Lawrence S. Bloomberg, C.M., O. Ont. MaRS board member to receive the honour of The Order of Canada.
Assunta Krehl

Pecaut Centre Announces Andrew Steele as new CEO - Canada Newswire - August 13, 2012 - 0 views

  •  
    The Pecaut Centre for Social Impact announces Andrew Steele as CEO. Dr. Ilse Treurnicht, CEO of MaRS Discovery District is a board member of the Pecaut Centre for Social Impact.
Assunta Krehl

Canadian innovations get to market faster - The Globe and Mail - May 25, 2012 - 1 views

  •  
    There is a need for enhancing commercialization, but there are gaps particularly in the lifesciences. Dr. Calvin Stiller, MaRS Board member states that there is a difference it testing and approval times in the commercialization of life sciences that still needs to be addressed.
Assunta Krehl

List of Canadians invested with the Order of Canada - CTV News - May 25, 2012 - 1 views

  •  
    Lawrence S. Bloomberg, C.M., O. Ont. is a MaRS board member who was one of the recipients to receive the honour of The Order of Canada.
Assunta Krehl

YFile - Symposium examines the path to breakthrough medicines - 0 views

  • Canada has the research expertise to develop drugs and vaccines to address pressing medical needs, but delivering on the promise will require new models of collaboration between scientists, biotechnology, the pharmaceutical industry, business and policy makers according to speakers at an upcoming symposium hosted by The Gairdner Foundation and York University. The symposium, Entrepreneurship & Commercialization in Biomedical Science, on Thursday, May 14, marks the 50th anniversary of both York University and The Gairdner Foundation.
  • The Gairdner Foundation recognizes the world's leading medical research scientists through its prestigious annual awards program for biomedical science. The symposium, which is hosted by York’s Faculty of Science & Engineering and Schulich School of Business, will bring together scientist entrepreneurs, Canadian venture capital firms, the biomedical industry and policy-makers.
  • He will be followed by Smith, founder and former president & CEO of RBC Ventures and a member of the board of Toronto's MaRS innovation centre. Smith will speak about how Canada has made strong progress in positioning itself as a potential leader in biotech and medical research and in its commercialization efforts but faces two clear threats – the global financial calamity together with the lack of clear federal government support for research.
  •  
    The symposium, Entrepreneurship & Commercialization in Biomedical Science, is being held on Thursday, May 14, which marks the 50th anniversary of both York University and The Gairdner Foundation. At this symposiums they will address the problem that Canadian researchers expertise to need to do in developing drugs and vaccines to address pressing medical needs. Mention of Susan Smith as a Board Member of MaRS Innovation.
Assunta Krehl

Canada's Gairdner Foundation announces 2010 winners - The Star - April 6, 2010 - 0 views

  •  
    The 2010 Canada Gairdner Awards honour groundbreaking medical research behind cancer, epilepsy and heart disease and malaria treatments. Dr. Calvin Stiller, Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada is a recipient for the 2010 Canada Gairdner Award.
Assunta Krehl

Medical research innovator gets double honour - The Globe and Mail - April 7, 2010 - 0 views

  •  
    MD-entrepreneur Cal Stiller, noted for advocating commercial development of research, wins Gairdner Award and hall of fame berth. Dr. Calvin Stiller is the Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada.
Assunta Krehl

CBC News - Winners of Gairdner medical prize unveiled - April 6, 2010 - 0 views

  •  
    The 2010 Canada Gairdner Awards honour groundbreaking medical research behind cancer, epilepsy and heart disease and malaria treatments. Dr. Calvin Stiller, Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada is a recipient for the 2010 Canada Gairdner Award.
Assunta Krehl

Gairdner winner urges need for greater Canadian medical research funding - Edmonton Jou... - 0 views

  •  
    Dr. Calvin Stiller, Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada is a recipient for the 2010 Canada Gairdner Award.
Assunta Krehl

Cancer chief wins precursor to Nobel - National Post - April 7, 2010 - 0 views

  •  
    Calvin Stiller, chairman of the Ontario Institute for Cancer Research, won the Canada Gairdner Wightman Award for his work on the use of cyclosporine as a treatment for organ transplant rejection, but also for his role as a scientific entrepreneur, and a rainmaker for major scientific projects. Dr. Calvin Stiller is the Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada.
Cathy Bogaart

Time for Canada to own the entrepreneurial podium - The Globe and Mail, Mar 16, 2011 - 0 views

  •  
    MaRS CEO, Ilse Treurnicht, and Board Member, John Manley, are both interviewed for the Action Canada report. This report recommends a national strategy for "owning the podium" in entrepreneurship.
Cathy Bogaart

Canadian Medical Hall of Fame: 2010 Induction - 0 views

  •  
    MaRS Board member Cal Stiller is inducted into the Canadian Medical Hall of fame.
Assunta Krehl

Richard W. Ivey joins Board of Directors at MaRS - Canada Newswire - 0 views

  •  
    MaRS Discovery District has appointed businessman and philanthropist Richard Ivey to its board of directors. Feb 19, 2009
Assunta Krehl

Gairdner winner urges need for greater Canadian medical research funding - Vancouver Su... - 0 views

  •  
    Dr. Calvin Stiller, Chair of Ontario Institute for Cancer Research, Board Member of MaRS Discovery District and past chair of Genome Canada is a recipient for the 2010 Canada Gairdner Award.
Assunta Krehl

Impact investing growing but more effort needed: report - The Globe and Mail - 0 views

  •  
    Tara Perkins, Globe and Mail reporter states "The Canadian Task Force on Social Finance says there is evidence that impact investing is growing as an asset class in this country.... more effort is require to make progress though." Ilse Treurnicht, the CEO of MaRS Discovery District is a member of the Task Force.
1 - 20 of 77 Next › Last »
Showing 20 items per page